Axial Therapeutics, Inc. is pioneering a novel approach to drug development by focusing on the gut microbiome's role in various neurological disorders and diseases. Their proprietary Microbial-Inspired Therapeutics® platform aims to identify and validate new drug targets within the microbiome, which is believed to significantly influence conditions such as autism spectrum disorder (ASD) and Parkinson's disease. The company is advancing a pipeline of gut-targeted small molecule therapeutics, with their lead candidate, AB-2004, currently undergoing a Phase 2b clinical trial for treating irritability associated with autism. This innovative therapy is designed to act on the gut-brain axis by sequestering neuroactive microbial metabolites, thereby minimizing systemic exposure and potential side effects.

The scientific foundation of Axial's approach is built on rigorous research that establishes causation between the microbiome and disease pathology. By employing advanced preclinical models and a multidisciplinary team of experts, Axial aims to demonstrate how specific microbial products contribute to disease severity and progression. Their research highlights the importance of the gut microbiome in regulating various bodily functions, including mood and immune response, and its potential impact on neurological health. Through this transformative therapeutic strategy, Axial Therapeutics seeks to develop first-in-class medicines that address significant unmet needs in the treatment of neurological disorders.

United States

Axial Therapeutics™ is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurodegenerative diseases.

Axial Therapeutics, Inc.

Company Details